Clinical trials: Anlotinib
Advanced Non-squamous NSCLC
Study of Anlotinib in Advanced Non-squamous NSCLC Patients in the Elderly Without Systemic Chemotherapy (ALTER-L006)
Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic research and development. It can inhibit the angiogenesis related kinase, such as VEGFR, FGFR, PDGFR, and tumor celltebiz related kinase -c-Kit kinase.
- Trial name
- NCT03778853
- Testing
- Anlotinib Hydrochloride
- Volunteers
- 72 people
- Sponsor
- LanZhou University
Cancer of Liver
Anlotinib in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
This is a prospective, one-arm, exploratory clinical study to observe and evaluate the efficacy and safety of Anlotinib hydrochloride capsules in patients with advanced liver cancer.
- Trial name
- ATAHC (NCT03766776)
- Testing
- Anlotinib
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Advanced Non-squamous NSCLC
Anlotinib Plus Pemetrexed or Pemetrexed for Previously Untreated Elderly (>=70) or PS=2 Non-squamous NSCLC
Evaluate the efficacy and safety of Anlotinib plus Pemetrexed as the 1-line treatment of patients with Platinum intolerant advanced non-squamous NSCLC, with Pemetrexed control.
- Trial name
- NCT03768037
- Testing
- Anlotinib plus Pemetrexed, Pemetrexed
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Guangdong Association of Clinical Trials
Carcinoma, Non-small Cell Lung Cancer
Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative
This is an efficacy and safety study of Anlotinib combined with Sintilimab (IBI 308) in participants with advanced or metastatic non-small cell lung cancer (NSCLC) who have received first-generation EGFR-TKIs resistance along…
- Conditions
- Carcinoma, Non-small Cell Lung Cancer, Lung Neoplasm
- Trial name
- NCT03765775
- Testing
- Sintilimab, Anlotinib Hydrochloride
- Where
- China
- Volunteers
- 20 people
- Sponsor
- First Hospital of Shijiazhuang City
Non-small Cell Lung Cancer
A Study of Anlotinib in Combination With Docetaxel Versus Docetaxel Alone in Participants With Advanced NSCLC
Evaluate the efficacy and safety of Anlotinib in combination with Docetaxel versus Docetaxel in patients with advanced non-small lung cancer after failure of first-line Chemotherapy .
- Trial name
- ALTER-L024 (NCT03732001)
- Testing
- Anlotinib combined Docetaxel, Docetaxel
- Where
- China
- Volunteers
- 80 people
- Sponsor
- China Medical University, China
Non Small Cell Lung Cancer
Anlotinib Combined With Docetaxel for Advanced Non-squamous Non-Small Cell Lung Cancer
Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic research and development. It can inhibit the angiogenesis related kinase, such as VEGFR, FGFR, PDGFR, and tumor cell proliferation related kinase -c-Kit…
- Trial name
- ACDFNSNSCLC (NCT03750916)
- Testing
- Anlotinib Hydrochloride plus Docetaxel
- Volunteers
- 46 people
- Sponsor
- Qilu Hospital of Shandong University
Non Small Cell Lung Cancer
Anlotinib Combined With Docetaxel for Advanced Non-Small Cell Lung Cancer（ALTER-L034）
Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic research and development. It can inhibit the angiogenesis related kinase, such as VEGFR, FGFR, PDGFR, and tumor cell proliferation related kinase -c-Kit…
- Trial name
- ACDFNSCLC (NCT03735264)
- Testing
- Anlotinib Hydrochloride plus Docetaxel
- Volunteers
- 46 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Recurrent Small Cell Lung Cancer
Anlotinib in Treatment of Recurrent Small Cell Lung Cancer
Exploring the efficacy and safety of Anlotinib in patients with relapsed small cell lung cancer
- Trial name
- NCT03732846
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Peking University Cancer Hospital & Institute
Non-Small-Cell Lung Cancer
Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung Adenocarcinoma
Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic research and development. It can inhibit the angiogenesis related kinase, such as VEGFR, FGFR, PDGFR, and tumor cell proliferation related kinase -c-Kit…
- Trial name
- NCT03728374
- Testing
- Anlotinib
- Volunteers
- 38 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
EGFR Gene Mutation
EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC
A single arm study: EGFR-TKIs Combine With Anlotinib as First-line Treatment in patients with EGFR-mutant non-small-cell lung cancer (NSCLC).
- Trial name
- NCT03720873
- Testing
- erlotinib or gefitinib or icotinib, Anlotinib
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Fujian Cancer Hospital
Lung Cancer, Lung Cancer Metastatic
Anlotinib Versus Docetaxel as the Second-line Treatment in EGFR Wild Type Patients With Advanced NSCLC
This study is conducted to explore the safety and efficacy of anlotinib, a tyrosine kinase inhibitors of Vascular Endothelial Growth Factor Receptor 2（VEGFR）、FGFR（Fibroblast Growth Factor Receptor）, Platelet-derived growth factor…
- Trial name
- NCT03703596
- Testing
- Anlotinib Hydrochloride, Docetaxel
- Where
- 10 sites in China
- Volunteers
- 88 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma
Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma
Gemcitabine plus cisplatin (GC) is more effective than fluorouracil plus cisplatin in the treatment of recurrent or metastatic NPC (R/M-NPC). GC is the standard first-line chemotherapy regimen for this population.
- Trial name
- NCT03639467
- Testing
- Anlotinib plus gemcitabine/cisplatin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chinese Academy of Medical Sciences
Non-squamous Non-small Cell Lung Cancer
Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and Cisplatin
Chemotherapy is still the standard first-line treatment option for EGFR unmutated patients. After a randomized phase Ⅲ trial, BEYOND was presented the synergistic effect of progression-free survival(PFS) could be expected when…
- Trial name
- NCT03671538
- Testing
- Anlotinib, pemetrexed, Cisplatin
- Volunteers
- 62 people
- Sponsor
- Lingyu Luo
Carcinoma, Non-Small-Cell Lung
Concurrent Chemoradiotherapy Combination With Anlotinib for Unresectable Stage III NSCLC Patients
The purpose of this study is to determine whether concurrent chemoradiotherapy combination with Anlotinib is safe, effective in the treatment of unresectable stage III NSCLC patients.
- Trial name
- NCT03672136
- Testing
- Anlotinib, Concurrent Chemoradiotherapy
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Shandong Cancer Hospital and Institute
Gastroenteropancreatic Neuroendocrine Tumor G3
A Study of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3
To assess the primary effects and safety of Anlotinib in patients with Gastroenteropancreatic Neuroendocrine Tumor G3.
- Trial name
- NCT03457844
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non-small Cell Lung Cancer
Anlotinib Plus Docetaxel for the Treatment of EGFR/ALK/ROS1 Mutation-negative Advanced Nonsquamous NSCLC
Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic research and development. It can inhibit the angiogenesis related kinase, such as VEGFR, FGFR, PDGFR, and tumor cell proliferation related kinase -c-Kit…
- Trial name
- NCT03654027
- Testing
- Anlotinib Plus Docetaxel, Docetaxel
- Volunteers
- 84 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
NSCLC, Adenocarcinoma
Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC
Non-small cell lung cancer has the highest morbidity and mortality in China，and platinum-based chemotherapy is the standard first-line treatment for the wild-type NSCLC,however the overall survival still less than one…
- Conditions
- NSCLC, Adenocarcinoma, Squamous Cell Carcinoma
- Trial name
- NCT03636685
- Testing
- Anlotinib combined with pemetrexed and carboplatin, phase I, Anlotinib combined with paclitaxel and carboplatin, phase I, Anlotinib combined with pemetrexed and carboplatin, phase II
- Volunteers
- 60 people
- Sponsor
- Chinese Academy of Medical Sciences
Lung Cancer, Advanced Stage
First-line Combination Treatment Based on Anlotinib
The aim of this study is to explore safety and therapeutic efficacy of anlotinib combined with erlotinib/chemotherapy/IBI308 as first-line treatment in advanced NSCLC patients.
- Trial name
- NCT03628521
- Testing
- Anlotinib，Erlotinib，IBI308，Pemetrexed，gemcitabine，carboplatin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Shanghai Chest Hospital
Colo-rectal Cancer
Safety and Efficacy of Anlotinib in Combination With Irinotecan in Patients With Pretreated Advanced Colorectal Cancer
Patients with pretreated advanced colorectal cancer are recruited to the phase I portion of this prospective non-randomised study in an escalated dose cohort.
- Trial name
- NCT03545711
- Testing
- Anlotinib Hydrochloride with Irinotecan
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Chinese Academy of Medical Sciences
Non-squamous Non-small Cell Lung Cancer
Phase I Study of the Combination of Anlotinib With Gefitinib
The purpose of this clinical study is to evaluate the tolerability and toxicity of different dose of Anlotinib puls Gefitinib in First-line Treatment of Advanced Gene Positive Non-squamous Non-small Cell Lung Cancer , to provide…
- Trial name
- NCT03602027
- Testing
- Anlotinib, Gefitinib
- Volunteers
- 9 people
- Sponsor
- Second Affiliated Hospital of Nanchang University